ResMed Strategy and Business Model

Executive Overview

ResMed is a global medical technology and healthcare software company focused on sleep apnea, chronic respiratory disease, and out-of-hospital care. Founded in 1989 in Australia and now headquartered in San Diego, ResMed sells cloud-connected positive airway pressure devices, masks, home ventilators, and digital health tools used by patients, sleep physicians, home medical equipment providers, hospitals, and post-acute care organizations. It also owns software platforms that serve durable medical equipment providers, skilled nursing facilities, senior living operators, home health agencies, and hospice organizations.

What makes ResMed strategically distinctive is that it is not only a device maker. Its model links diagnosis, device setup, adherence monitoring, patient engagement, replacement supplies, and provider workflow software into one connected ecosystem. That gives the company a mix of hardware revenue, recurring mask and accessory resupply, and subscription-style software revenue. As of fiscal 2024 company materials, ResMed served customers in more than 140 countries, with the United States as its largest market. Revenue for fiscal 2024 was $4.69B, underscoring ResMed’s scale in sleep health, respiratory care, and healthcare software.

ResMed at a Glance

Logo
Common name	ResMed
Full legal name	ResMed Inc.
Headquarters	San Diego, California, United States
Ownership	Public company; widely held institutional ownership, with no controlling shareholder publicly disclosed in recent filings.
Ticker	RMD
Exchange	NYSE - New York Stock Exchange
Market Cap	$27.72B
Revenue (FY2024)	$4.69B
Founding / major historical milestones	Founded in 1989 in Australia to commercialize sleep-disordered breathing technology; expanded globally in sleep and respiratory care; broadened into healthcare software through acquisitions including Brightree (2016), MatrixCare (2018), and MEDIFOX DAN (2022).
Industry or industries	Medical technology, sleep health, respiratory care, digital health, healthcare software
Key products or services	Continuous positive airway pressure (CPAP) and bilevel devices, masks and accessories, home ventilators, patient engagement and remote monitoring software, post-acute care and durable medical equipment software
Geographic footprint	Global; as of recent company materials, serves more than 140 countries, with major businesses in the Americas, Europe, and Asia-Pacific
Business segments as officially reported	ResMed has historically been managed as one reportable segment in SEC filings; commercially, management discusses Sleep and Respiratory Care and Software-as-a-Service portfolios.
Company website	https://www.resmed.com/

1. What Is the Strategy of ResMed?

Based on ResMed’s fiscal 2023 annual report and fiscal 2024 investor communications available through April 2024, the company’s strategy is best understood as a connected-care strategy for sleep health, respiratory care, and out-of-hospital care. It combines medical devices, masks, cloud software, patient engagement, and provider workflow tools rather than treating these as separate businesses.

1. 1a. What is the winning aspiration of ResMed?

   ResMed’s public aspiration is broader than selling CPAP machines. Management consistently frames the company around improving lives by helping people sleep better, breathe better, and receive more care outside the hospital. In recent company materials, ResMed has also articulated a goal of improving 250 million lives by 2025. In practical strategic terms, “winning” means expanding the diagnosed and treated population for sleep-disordered breathing and chronic respiratory disease, improving therapy adherence, lowering the total cost of care for providers and payers, and building a durable stream of recurring revenue around connected devices, consumables, and software.

2. 1b. Where does ResMed play?

   ResMed plays in several linked fields: sleep apnea diagnosis and treatment, home respiratory care, non-invasive ventilation, and software for out-of-hospital care. It targets both clinical buyers and operational buyers: sleep labs, physicians, hospitals, home medical equipment providers, respiratory therapists, skilled nursing facilities, senior living operators, home health providers, and hospice organizations. Geographically, it plays globally, with a particularly strong presence in the United States and meaningful operations across Europe and Asia-Pacific.

3. 1c. How does ResMed plan to win?

   ResMed does not appear to compete primarily on lowest price. Its recipe for winning is a premium-value proposition built on clinical efficacy, mask comfort, device connectivity, patient adherence support, and workflow software for providers. The company’s device business is stronger when patients remain compliant and reorder masks and accessories; its software business is stronger when providers rely on ResMed systems for billing, operations, and care coordination. That creates a strategy centered on ecosystem value, not just hardware placement. The company also benefits when it can help providers work more efficiently in labor-constrained care settings.

4. 1d. What capabilities must ResMed have in place?

   To execute this strategy, ResMed needs strong product design and clinical research capabilities, medical-device regulatory expertise, reliable manufacturing and sourcing, cloud software and cybersecurity capabilities, and deep commercial relationships with providers and channel partners. It also needs software integration and acquisition-integration skills because part of its strategy has been to add workflow software businesses that broaden its presence across the care continuum.

5. 1e. What management systems does ResMed require?

   ResMed requires management systems that are tighter than those of a typical consumer-device company because it operates in regulated healthcare. That includes quality systems, post-market surveillance, regulatory compliance, cybersecurity governance, and clinical evidence generation. On the operating side, the company also needs demand planning, gross-margin management, inventory and logistics controls, subscription-software metrics, and connected-device data systems that track adherence, resupply, and customer retention. Those systems reinforce the strategy by tying product performance, patient outcomes, and recurring economics together.

2. What Are the Current Strategic Initiatives of ResMed?

As reflected in fiscal 2024 earnings materials and management commentary available through April 2024, ResMed’s near-term agenda has been concrete and operational, not abstract.

• Meet elevated device demand while normalizing supply economics. A major priority through fiscal 2023 and fiscal 2024 was serving unusually strong demand in sleep devices, including demand displaced by the Philips Respironics recall, while reducing expedited freight, component inflation, and other supply-chain costs that had pressured gross margin.
• Expand the AirSense 11 and newer mask portfolio globally. ResMed has continued to roll out newer-generation sleep devices and mask offerings across markets. That matters because refreshed devices and premium masks support adherence, pricing, and replacement demand.
• Deepen digital engagement around therapy adherence. ResMed has kept investing in connected care tools such as myAir for patients and AirView for providers. The strategic aim is to improve patient onboarding, compliance, and clinical follow-up while making therapy management less labor-intensive for providers.
• Grow software in out-of-hospital care. Through businesses such as Brightree, MatrixCare, MEDIFOX DAN, and more recent tuck-ins, ResMed has been building a larger software footprint across durable medical equipment, post-acute care, and home-based care. The initiative is not just software growth for its own sake; it broadens ResMed’s role in the care workflow around the patient.
• Help providers operate more efficiently in labor-constrained settings. A recurring theme in company messaging is that homecare and post-acute providers face staffing shortages, documentation burdens, and reimbursement complexity. ResMed’s strategy is to sell workflow efficiency as well as clinical products.
• Use disciplined M&A to add capabilities. ResMed has shown a pattern of buying software and digital health assets that extend its reach in diagnostics, care coordination, or post-acute operations. That suggests its strategic initiatives include portfolio expansion where acquired capabilities make the core ecosystem more useful.

3. What Is the Business Model of ResMed?

ResMed’s business model combines medical-device sales with recurring consumables and software subscriptions. That mix is important because it makes the company economically different from a pure device manufacturer.

• What customers actually buy. Providers and channel partners buy sleep devices, bilevel devices, ventilators, masks, tubing, humidification accessories, and related supplies. Healthcare organizations also buy software for billing, clinical workflow, care coordination, and post-acute operations. Patients, indirectly or directly depending on market structure, buy comfort, convenience, adherence support, and a trusted therapy experience.
• Recurring or repeat-driven versus one-time. Devices are more episodic purchases, although installed-base expansion matters. Masks, cushions, tubing, filters, and related accessories are naturally repeat-driven because they require replacement over time. Software revenue is typically subscription-like and recurring. This is why ResMed’s installed base matters so much: once a patient is on therapy, recurring resupply and monitoring economics can follow.
• How pricing power works. ResMed appears to have some pricing power in premium products because comfort, reliability, digital connectivity, and clinical support matter to buyers. That said, pricing is not unconstrained. Reimbursement schedules, tenders, provider purchasing power, and competition all limit how far pricing can move.
• Why the business mix matters. Masks and accessories tend to be attractive because they attach to the installed base and repeat over time. Software adds recurring revenue, customer stickiness, and a higher-value role in care workflows. Devices are still essential because they create the installed base that supports everything else.
• What drives gross margin, operating margin, and cash generation. Gross margin is influenced by mix, manufacturing utilization, component costs, freight, and the share of higher-margin software and consumables. Operating margin depends on commercial efficiency, software scale, and R&D discipline. Cash generation benefits from relatively modest capital intensity compared with heavy industrial manufacturing, though inventory swings can matter during supply disruptions.
• Revenue model. The model is a blend of one-time device revenue, recurring replacement-supply revenue, and subscription-style software revenue. That hybrid structure is a core part of the investment case and strategic logic.

4. What Products and Services Does ResMed Sell?

As of fiscal 2024 product and investor materials, ResMed’s offerings fall into four main categories.

• Sleep health devices. These include CPAP, automatic positive airway pressure, and bilevel devices used to treat obstructive sleep apnea and related sleep-disordered breathing conditions. AirSense and AirCurve are among the company’s best-known product families. These products are central to the installed base.
• Masks and accessories. ResMed sells a broad mask portfolio, including nasal, nasal pillow, and full-face masks, plus cushions, headgear, tubing, and related components. These products are strategically important because they affect comfort and adherence and generate recurring replacement demand.
• Home respiratory care and ventilation. ResMed also sells devices for patients with more complex respiratory needs, including non-invasive ventilation and portable ventilators used in home and some institutional settings. Brands such as Astral, Lumis, and Stellar sit in this category.
• Digital health and healthcare software. ResMed’s platforms include patient engagement and remote monitoring tools such as myAir and AirView, plus enterprise software businesses such as Brightree, MatrixCare, and MEDIFOX DAN. These serve providers in durable medical equipment, senior care, home health, hospice, and other out-of-hospital settings.

The core sleep device and mask ecosystem appears to drive the largest share of revenue and profit. Software is smaller in absolute terms but strategically important because it adds recurring revenue and widens ResMed’s role in the care process. In that sense, software is a growth and positioning engine, while sleep therapy remains the economic backbone.

5. What Are the Key Competitors or Peers of ResMed?

ResMed has no perfect single comparator because it combines sleep and respiratory devices with healthcare software. Its competitive set therefore spans both medical technology and post-acute care software.

• Philips Respironics — Historically the closest global competitor in CPAP, bilevel, and sleep therapy devices. Philips’ recall materially disrupted its sleep franchise after 2021, but it remains an important reference point in the category.
• Fisher & Paykel Healthcare — Competes in respiratory care and sleep-related interfaces, with strength in humidification and masks. Often viewed as a serious product competitor in respiratory and sleep-adjacent areas.
• Drive DeVilbiss Healthcare — Competes in home respiratory equipment and other homecare categories, especially through channel relationships and value-oriented offerings.
• Löwenstein Medical — A notable sleep and respiratory care competitor, especially in parts of Europe.
• Inspire Medical Systems — Not a direct CPAP equivalent, but an alternative therapy for certain obstructive sleep apnea patients, making it a substitute in selected clinical cases.
• PointClickCare — A software peer in senior care and post-acute healthcare information systems, relevant to ResMed’s MatrixCare business.
• WellSky — A healthcare software competitor in home health, post-acute care, and care coordination.
• Netsmart — Competes in healthcare software serving community-based care, behavioral health, and home-based care settings.

The most important point is that ResMed competes differently by category. In devices, product performance, comfort, and channel execution matter most. In software, workflow fit, integration, billing functionality, and retention matter more.

6. What Is the Marketing Strategy of ResMed?

ResMed’s marketing strategy is primarily clinical and channel-oriented rather than mass-market consumer advertising. Because most sleep and respiratory products are prescribed, reimbursed, or provider-mediated, the company’s marketing has to support referral pathways, clinical adoption, and channel confidence.

• Clinical evidence and education. ResMed invests in evidence-based marketing that emphasizes therapy effectiveness, adherence, comfort, and workflow efficiency. In medtech categories like these, clinical credibility is often more valuable than broad brand awareness alone.
• Channel marketing. Home medical equipment providers, sleep labs, distributors, and healthcare systems play a major role in product selection and patient setup. ResMed therefore markets heavily through partner enablement, training, events, and sales support.
• Patient engagement as a marketing extension. Tools such as myAir help patients stay engaged after setup. That is partly a clinical tool and partly a retention tool, because adherence supports long-term resupply and brand loyalty.
• Enterprise marketing for software. The software businesses rely more on account-based and field-oriented marketing, including trade shows, provider thought leadership, workflow improvement messaging, and direct enterprise selling.

Brand matters for ResMed, especially in masks and sleep therapy, but marketing appears to be a supporting capability rather than the company’s main differentiator. The deeper differentiators are product design, digital connectivity, installed-base economics, and provider workflow integration.

7. What Are the Key Customer Segments of ResMed?

As of fiscal 2024, ResMed’s customers span a broad set of healthcare intermediaries and end users, but they are united by one theme: care delivered outside the traditional acute hospital setting.

• Sleep physicians, sleep labs, and diagnostic providers. These stakeholders influence diagnosis and treatment initiation for sleep apnea and related conditions.
• Home medical equipment providers and durable medical equipment companies. These are among ResMed’s most important channel customers because they dispense devices, manage reimbursement documentation, and handle ongoing resupply.
• Hospitals and health systems. They matter especially for respiratory care and discharge pathways into home-based therapy.
• Patients and caregivers. Patients may not always be the direct payer, but they are crucial economic actors because comfort and adherence shape replacement demand and brand preference.
• Post-acute care providers. Through MatrixCare, Brightree, and related software assets, ResMed serves skilled nursing, senior living, home health, hospice, and home-based care organizations.
• Distributors and international channel partners. These matter more in markets where local channel structure, reimbursement, or service infrastructure differs from the U.S. model.

ResMed is diversified across customer types, but it remains concentrated around sleep health and out-of-hospital care. That focus is a strength because it lets the company build a specialized ecosystem, though it also ties performance to reimbursement, diagnosis rates, and provider operating conditions in those markets.

8. What Is the Sales Model of ResMed?

ResMed’s sales model is best described as B2B2C: it usually sells through professional and institutional channels that then serve the patient.

• Device sales through providers and channel partners. In many markets, ResMed sells sleep and respiratory devices through home medical equipment companies, distributors, sleep labs, hospitals, and national provider accounts rather than directly to end consumers.
• Software sold through direct enterprise sales. Software businesses such as Brightree and MatrixCare typically use a direct sales model aimed at provider organizations, administrators, and operational leaders.
• Digital tools that support retention rather than replace channels. ResMed’s patient-facing apps and cloud tools improve adherence and engagement, but they generally complement the prescription and provider channel instead of disintermediating it.
• Channel structure affects pricing and intimacy. Because providers and distributors control setup, service, and reimbursement paperwork, channel relationships are strategically important. That can make growth slower than pure direct-to-consumer models, but it also creates switching costs and more embedded customer relationships.

For consultants, this channel complexity is relevant: growth is often constrained less by end-user awareness alone than by diagnosis capacity, provider staffing, reimbursement processes, and partner economics.

9. In What Geographies Does ResMed Operate?

As of fiscal 2024 company materials, ResMed had a broad international footprint, serving more than 140 countries. The company is global, but not geographically neutral: the United States is its largest market, and much of its software business is U.S.-centric.

• Americas. The U.S. is the company’s largest commercial market and the center of much of its sleep therapy and software activity. Canada and Latin America add additional device and channel opportunities, though at smaller scale.
• Europe, Middle East, and Africa. Europe is an important region for sleep and respiratory devices and for software following the MEDIFOX DAN acquisition in Germany. Market structures vary by reimbursement system and tender dynamics.
• Asia-Pacific. Australia is important historically and operationally, while Asia-Pacific also matters for manufacturing, distribution, and long-term growth. Singapore has been a key manufacturing location in company disclosures.

Operationally, ResMed’s footprint includes headquarters and major commercial operations in the United States, heritage and engineering ties to Australia, manufacturing in Asia-Pacific, and a distributed network of sales, service, and software operations across Europe and other international markets. The business is internationally diversified, but still meaningfully weighted toward U.S. healthcare channels.

10. Who Are the Owners of ResMed?

ResMed is a publicly traded company. As reflected in 2024 public shareholding disclosures, ownership was primarily institutional, with large asset managers such as Vanguard, BlackRock, and State Street among the significant shareholders. No controlling shareholder was publicly disclosed in recent filings. That ownership structure is typical of a mature public medtech company and means governance is driven mainly by the board, management, and institutional investor expectations rather than by a founder-controlled voting bloc.

11. How Is ResMed Organized?

ResMed’s legal parent is ResMed Inc., but operationally the company is easier to understand as a connected portfolio organized around products, software, and regions.

• Core sleep and respiratory care portfolio. This includes devices, masks, accessories, and ventilation products.
• Software and digital health portfolio. This includes Brightree, MatrixCare, MEDIFOX DAN, and related digital platforms that support out-of-hospital care.
• Regional commercial organizations. Sales and service are adapted by region because reimbursement, channel structure, and regulatory requirements differ across markets.
• Central functions. R&D, quality, regulatory, manufacturing, supply chain, finance, and IT operate across the portfolio.

In SEC reporting, ResMed has historically presented itself as one reportable segment. That accounting view is useful, but the practical business model has two economic engines: hardware and masks on one side, and software and digital workflow tools on the other.

12. How Does ResMed Operate?

ResMed’s day-to-day operation is built around a care pathway, not just a factory-and-distributor model.

1. Diagnosis and prescription. A patient is identified with sleep apnea or a respiratory condition through physicians, sleep labs, home testing, or other clinical pathways.
2. Device and mask fulfillment. ResMed manufactures or assembles devices and masks, then supplies them through home medical equipment providers, distributors, hospitals, or other channels.
3. Patient setup and onboarding. Providers set up therapy, fit masks, and manage reimbursement documentation. ResMed’s digital tools support this step.
4. Remote monitoring and adherence. Connected devices transmit usage data to platforms such as AirView, while patients use tools such as myAir. This helps providers monitor compliance and adjust support.
5. Recurring resupply. Over time, patients need replacement masks, cushions, tubing, and other accessories. This is a key value driver because it turns installed-base growth into recurring revenue.
6. Provider workflow support. Through Brightree, MatrixCare, and related software, ResMed also helps providers manage billing, documentation, scheduling, clinical operations, and care coordination.

The main operating complexities are reimbursement rules, global medical-device quality requirements, component supply, demand forecasting, and the challenge of serving labor-constrained healthcare providers. ResMed creates value when it makes this workflow easier and more reliable for both caregivers and patients.

13. What Are the Growth Opportunities for ResMed?

ResMed’s most plausible growth opportunities, based on public materials through fiscal 2024 and reasonable external synthesis, are tied to underdiagnosis, digital workflow expansion, and installed-base monetization.

• Expanding diagnosis and treatment of sleep apnea. Sleep apnea remains significantly underdiagnosed globally. More screening, better home diagnostics, and stronger referral pathways can expand the total treated market.
• Installed-base growth in sleep therapy. Every additional device in the field can support future mask and accessory resupply. This gives ResMed leverage from device placements beyond the initial sale.
• International expansion. Many non-U.S. markets still offer runway in diagnosis, reimbursement development, and adoption of newer devices and masks.
• Software cross-sell in out-of-hospital care. ResMed can deepen relationships with post-acute and home-based care providers by bundling workflow, billing, engagement, and analytics capabilities across acquired software assets.
• Respiratory care and home ventilation. Aging populations, chronic disease prevalence, and healthcare systems’ interest in lower-cost home care create room for growth beyond core sleep therapy.
• Digital health and analytics. Better use of connected-device data can improve adherence, reduce provider workload, and make ResMed’s ecosystem more valuable.
• Selective M&A. ResMed has shown that it will use acquisitions to add workflow software, diagnostics, and care-management capabilities.

The main constraints are reimbursement pressure, regulatory complexity, competition, provider labor shortages, supply-chain execution, and uncertainty around how new therapies or clinical alternatives could affect parts of the sleep market over time.

14. What Is the History of ResMed?

ResMed was founded in 1989 in Australia by Dr. Peter Farrell to commercialize technology related to positive airway pressure therapy for sleep-disordered breathing. The company’s roots are closely tied to the pioneering sleep apnea work of Professor Colin Sullivan at the University of Sydney.

• 1989: ResMed is founded in Australia, initially focused on sleep apnea treatment technology.
• 1990s: The company expands commercially and becomes publicly listed in Australia, later adding a U.S. listing as it globalizes the business.
• 2000s: ResMed grows into a major global sleep and respiratory care company, expanding its product portfolio, geographic reach, and manufacturing footprint.
• 2016: The acquisition of Brightree marks a major step into healthcare software, especially for durable medical equipment providers.
• 2018: MatrixCare and Propeller Health broaden the company’s position in post-acute software and digital respiratory health.
• 2021 onward: The Philips Respironics recall reshapes the competitive landscape in sleep therapy, increasing demand for ResMed products.
• 2022 and after: Acquisitions such as MEDIFOX DAN, mementor, Citus Health, and Somnoware extend ResMed deeper into out-of-hospital care software and digital health.

The company’s history shows a clear evolution: from a specialist sleep-device maker to a broader connected-care platform spanning hardware, data, and healthcare software.

15. What Are the Key Suppliers to ResMed?

Suppliers matter to ResMed because its products depend on reliable access to specialized medical-device components and high-quality manufacturing inputs. Public disclosures do not provide a broad named supplier list, so the more useful way to think about the supplier base is by category.

• Electronic components and semiconductors. These are important for connected devices, wireless functionality, and control systems.
• Motors, blowers, and specialized mechanical parts. These components are central to airflow performance and device reliability.
• Medical-grade plastics, silicone, textiles, and foam alternatives. These are especially important for masks, cushions, tubing, and patient-contact components.
• Packaging, sterilization-related inputs, and quality-testing services. Regulated products require high consistency and traceability.
• Cloud, connectivity, and enterprise technology vendors. ResMed’s connected-care model also relies on digital infrastructure, not just physical parts.
• Logistics and freight providers. As management commentary in fiscal 2023 and fiscal 2024 made clear, freight cost and service levels can materially affect margins and service quality.

Supplier structure matters strategically because ResMed cannot simply swap components in the way a low-regulation consumer electronics firm might. Validation, quality systems, and medical-device compliance make supplier resilience a real competitive issue.

16. What Are the Key Brands Owned by ResMed?

Branding is important to ResMed, especially in sleep therapy and software, though the role of brand is more functional and trust-based than lifestyle-driven.

• ResMed — The master brand, associated with sleep therapy, respiratory care, and connected health.
• AirSense — Flagship sleep therapy device family and one of the most important brands in the portfolio.
• AirCurve — Bilevel therapy device family for more complex breathing support needs.
• AirMini — Portable travel-focused sleep therapy device brand.
• AirFit and AirTouch — Major mask families that matter both clinically and economically because masks drive adherence and recurring replacement demand.
• Astral, Lumis, and Stellar — Respiratory care and ventilation brands used in more complex care settings.
• myAir and AirView — Digital brands that anchor patient engagement and provider monitoring.
• Brightree, MatrixCare, and MEDIFOX DAN — Software brands that matter in their own right within homecare, post-acute care, and residential care workflows.

In ResMed’s case, brands are less about consumer aspiration and more about trust, fit, workflow familiarity, and clinical reliability.

17. How Is ResMed Using AI?

Public disclosures through fiscal 2024 suggest that ResMed talks more about connected devices, data, analytics, and algorithms than about stand-alone artificial intelligence products. Even so, several AI-adjacent uses are visible.

• Therapy and monitoring algorithms in live products. ResMed’s connected devices and digital platforms use embedded algorithms to monitor usage, detect sleep-related events, support therapy management, and improve adherence workflows. These are live operational capabilities, not just pilots.
• Patient engagement and personalization. Tools such as myAir use data-driven engagement to encourage compliance and support patients after setup. Publicly, this is usually described as digital coaching, analytics, or personalization rather than as a separate AI product line.
• Workflow automation in software. In its out-of-hospital software businesses, ResMed uses automation and data tools to help providers manage billing, documentation, and operational workflows. Some of this likely overlaps with machine learning or rules-based intelligence, though company disclosures often describe the value in workflow terms instead of technical AI terms.

A fair reading is that ResMed already uses applied analytics and algorithmic intelligence in production, but its public positioning has been pragmatic: use data to improve care and efficiency, rather than market AI as an end in itself.

18. How Does the Supply Chain of ResMed Function?

Supply chain is strategically important for ResMed because the company sells regulated devices, masks, and software-linked products that must be available when patients need therapy. As management commentary during fiscal 2023 and fiscal 2024 showed, supply-chain execution directly affects revenue, gross margin, and customer service.

1. Sourcing. ResMed procures electronic components, mechanical parts, plastics, textiles, and packaging from a global supplier base.
2. Manufacturing and assembly. The company uses a combination of owned operations and external manufacturing support, with Singapore and Australia often cited in company materials as important operating locations.
3. Quality and regulatory control. Medical-device supply chains require lot traceability, validation, testing, and documentation. This reduces flexibility but is essential to compliance.
4. Distribution. Products move through regional distribution networks to home medical equipment providers, distributors, hospitals, and other customers.
5. Resupply logistics. Replacement masks, cushions, tubing, and other accessories must be replenished reliably. That recurring logistics capability is economically important.
6. Service and digital continuity. Because the products are connected, supply-chain performance also has a digital component: activation, connectivity, data flow, and software uptime all affect the customer experience.

What makes the supply chain strategically important is not just cost. Reliability, speed, component availability, and the ability to avoid expedited freight all shape margin and market share in a category where therapy interruption is a serious issue.

19. What Is the Technology Strategy of ResMed?

Technology is central to ResMed’s competitiveness in two ways: it is part of the customer offering, and it is also an internal operating enabler.

• Connected devices as a platform. ResMed’s sleep and respiratory products are not just standalone hardware. Connectivity allows the company and its provider customers to monitor usage, troubleshoot issues, and improve compliance.
• Cloud software for providers and patients. Platforms such as AirView and myAir extend the value of the device after the sale. This creates data-driven customer relationships and helps lock the company into care workflows.
• Healthcare workflow software. Through Brightree, MatrixCare, and other assets, ResMed has made software a strategic pillar. This turns technology into a route for broader customer ownership in out-of-hospital care.
• Interoperability, cybersecurity, and data stewardship. Because ResMed handles medical and operational data, trust in uptime, privacy, and system reliability is a core technology issue.

The strategic aim is to make technology part of an integrated ecosystem: diagnose, set up therapy, monitor adherence, reorder supplies, and manage provider workflows in a connected way. That is a stronger position than simply selling a device at the point of prescription.

20. What Is the R&D Strategy of ResMed?

R&D is important to ResMed because product comfort, ease of use, and therapy efficacy are central to adherence. In sleep therapy, a technically adequate device is not enough; patients have to keep using it.

• Mask innovation. ResMed appears to prioritize fit, comfort, seal quality, and patient acceptance. This is strategically important because masks influence both therapy success and recurring replacement revenue.
• Device design and algorithms. The company continues to improve airflow performance, connectivity, usability, and digital support in sleep and respiratory devices.
• Miniaturization and convenience. Products such as AirMini reflect a focus on portability and patient lifestyle fit.
• Digital and software development. R&D is not limited to hardware. ResMed also invests in patient engagement platforms, provider workflow tools, and software interoperability.
• Clinical evidence and regulatory support. In medtech, R&D includes testing, validation, and evidence generation needed for market access and product updates.

The R&D strategy supports ResMed’s broader business model by improving adherence, protecting premium positioning, and making the connected ecosystem more useful to providers and patients.

21. What Is the Finance Strategy of ResMed?

ResMed’s finance strategy, as inferred from fiscal 2023 and fiscal 2024 disclosures, is to fund organic innovation, maintain balance-sheet flexibility, improve margins after supply disruptions, and use cash flow to support both shareholder returns and selective acquisitions.

• Margin recovery matters. Through fiscal 2023 and fiscal 2024, a major financial priority was restoring gross margin after component shortages and freight inflation. This was not just a finance issue; it was an operational strategic priority.
• Recurring mix improves quality of earnings. Consumables and software subscriptions support visibility and cash generation compared with a pure hardware model.
• Disciplined capital allocation. ResMed has a history of investing in R&D, acquiring software assets, paying a dividend, and at times repurchasing shares. The pattern suggests balance rather than aggressive financial engineering.
• Use debt selectively, then deleverage. Large software acquisitions have at times added leverage, but the company has generally used cash generation to bring leverage back down.
• Working capital discipline. Inventory and supply commitments matter more when component availability is tight, making working capital a real strategic lever.

Overall, the finance strategy supports the corporate strategy by preserving the ability to invest in products and software while keeping the company resilient through supply and reimbursement volatility.

22. What Major Acquisitions Has ResMed Made?

Acquisitions have played an important role in ResMed’s evolution from a device-focused company into a broader out-of-hospital care platform. The company’s deal pattern has been focused and strategic rather than purely roll-up driven.

The pattern is clear: ResMed uses M&A to move upstream into diagnostics, downstream into provider workflows, and laterally into adjacent software categories that make its overall ecosystem more valuable.

23. How Companies Like ResMed Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like ResMed use Umbrex when they want the problem-solving approach of top-tier consulting talent without hiring a full consulting team and its associated overhead. For a company with ResMed’s mix of medtech, software, supply chain, reimbursement, and digital health priorities, that flexibility can be especially useful.

Representative projects Umbrex consultants could support for a company like ResMed include:

• Sleep market growth strategy. Quantify where diagnosis bottlenecks sit across referral pathways, home sleep testing, channel partners, and geographies, then identify the highest-return growth moves.
• DME and provider channel optimization. Redesign channel segmentation, account coverage, partner incentives, and service models for home medical equipment providers and respiratory channels.
• Gross-margin recovery program. Identify sourcing, freight, inventory, and product-mix opportunities to improve margin without undermining service levels or regulatory quality.
• Software cross-sell strategy. Build a practical commercial plan to cross-sell Brightree, MatrixCare, MEDIFOX DAN, Citus Health, and device-adjacent offerings across out-of-hospital care customers.
• Post-merger integration. Support integration of acquired software businesses, including operating model design, synergy tracking, go-to-market alignment, and shared-services planning.
• AI and analytics roadmap. Prioritize use cases in patient adherence, resupply forecasting, customer support automation, provider workflow intelligence, and revenue-cycle optimization.
• International expansion strategy. Evaluate where newer device platforms, masks, or software can scale fastest based on reimbursement rules, distributor strength, and local competitive intensity.
• Pricing and reimbursement strategy. Assess product positioning, value communication, and tender or reimbursement economics by market and by product line.
• Supply-chain resilience and S&OP redesign. Improve sales and operations planning, supplier risk management, allocation logic, and inventory policies for critical components and recurring accessories.
• Portfolio and M&A screening. Develop a build-buy-partner roadmap for sleep diagnostics, home-based care software, adjacent respiratory technologies, or workflow automation capabilities.